Alverine CitrateCAS# 5560-59-8 |
- Sivelestat sodium salt
Catalog No.:BCC2368
CAS No.:150374-95-1
- ARP 100
Catalog No.:BCC2370
CAS No.:704888-90-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 5560-59-8 | SDF | Download SDF |
| PubChem ID | 21718 | Appearance | Powder |
| Formula | C26H35NO7 | M.Wt | 473.56 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 22 mg/mL (46.46 mM; Need ultrasonic and warming) | ||
| Chemical Name | N-ethyl-3-phenyl-N-(3-phenylpropyl)propan-1-amine;2-hydroxypropane-1,2,3-tricarboxylic acid | ||
| SMILES | CCN(CCCC1=CC=CC=C1)CCCC2=CC=CC=C2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O | ||
| Standard InChIKey | RYHCACJBKCOBTJ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H27N.C6H8O7/c1-2-21(17-9-15-19-11-5-3-6-12-19)18-10-16-20-13-7-4-8-14-20;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-8,11-14H,2,9-10,15-18H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Alverine Citrate Dilution Calculator
Alverine Citrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1117 mL | 10.5583 mL | 21.1166 mL | 42.2333 mL | 52.7916 mL |
| 5 mM | 0.4223 mL | 2.1117 mL | 4.2233 mL | 8.4467 mL | 10.5583 mL |
| 10 mM | 0.2112 mL | 1.0558 mL | 2.1117 mL | 4.2233 mL | 5.2792 mL |
| 50 mM | 0.0422 mL | 0.2112 mL | 0.4223 mL | 0.8447 mL | 1.0558 mL |
| 100 mM | 0.0211 mL | 0.1056 mL | 0.2112 mL | 0.4223 mL | 0.5279 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Alverine citrate is a drug used for functional gastrointestinal disorders.
- Alliin
Catalog No.:BCN3869
CAS No.:556-27-4
- H-D-Tyr-OH
Catalog No.:BCC3134
CAS No.:556-02-5
- Acesulfame Potassium
Catalog No.:BCC4755
CAS No.:55589-62-3
- Agrimol B
Catalog No.:BCN5017
CAS No.:55576-66-4
- Boc-Phe(4-NH2)-OH
Catalog No.:BCC3153
CAS No.:55533-24-9
- H-1-Nal-OH
Catalog No.:BCC3282
CAS No.:55516-54-6
- Biondinin C
Catalog No.:BCN5744
CAS No.:55511-08-5
- 6-Shogaol
Catalog No.:BCN6288
CAS No.:555-66-8
- CCCP
Catalog No.:BCC5658
CAS No.:555-60-2
- Tritetradecanoin
Catalog No.:BCN8389
CAS No.:555-45-3
- Methyldopa
Catalog No.:BCC4676
CAS No.:555-30-6
- Myriceric acid B
Catalog No.:BCN5743
CAS No.:55497-79-5
- 1-Oxo-4-hydroxy-2-en-4-ethylcyclohexa-5,8-olide
Catalog No.:BCN1417
CAS No.:55604-88-1
- Aristololactam II
Catalog No.:BCN8095
CAS No.:55610-00-9
- Cepharadione A
Catalog No.:BCN3950
CAS No.:55610-01-0
- Cepharadione B
Catalog No.:BCN6524
CAS No.:55610-02-1
- Syneilesine
Catalog No.:BCN2144
CAS No.:55652-65-8
- Deltonin
Catalog No.:BCC8933
CAS No.:55659-75-1
- Boc-D-Thr-OH
Catalog No.:BCC3453
CAS No.:55674-67-4
- TCN 213
Catalog No.:BCC6123
CAS No.:556803-08-8
- 1-Octacosanol
Catalog No.:BCN2973
CAS No.:557-61-9
- (24S)-24,25-Dihydroxyvitamin D3
Catalog No.:BCC1290
CAS No.:55700-58-8
- Secalciferol
Catalog No.:BCC1942
CAS No.:55721-11-4
- Salinomycin sodium salt
Catalog No.:BCC1917
CAS No.:55721-31-8
[A case report of alverine-citrate-induced acute hepatitis].[Pubmed:20375645]
Korean J Hepatol. 2010 Mar;16(1):75-8.
Alverine Citrate is one of the most commonly used antispasmodic drugs for patients with irritable bowel syndrome. Alverine-citrate-induced hepatotoxicity is extremely rare, with only a few cases having been reported worldwide. We present a case of a 75-year-old female patient who experienced complicated jaundice and abdominal discomfort after taking Alverine Citrate. Other causes of hepatitis were ruled out and the results of the liver function test returned to normal after ceasing the drug. This is the first case report in Korea of alverine-citrate-induced hepatotoxicity.
On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study.[Pubmed:24147869]
Int J Clin Pract. 2014 Feb;68(2):245-54.
BACKGROUND: In routine practice, irritable bowel syndrome (IBS) symptoms are often difficult to be relieved and impair significantly patients' quality of life (QoL). A randomised, double-blind, placebo-controlled study has shown the efficacy of Alverine Citrate/simeticone (ACS) combination for IBS symptom relief. AIM: As IBS symptoms are often intermittent, this pragmatic study was designed to compare the efficacy of an on-demand ACS treatment vs. that of usual treatments. METHODS: Rome III IBS patients were enrolled by 87 general practitioners who were randomly allocated to one of two therapeutic strategies: on-demand ACS or usual treatment chosen by the physician. The primary outcome measure was the improvement of the IBSQoL score between inclusion and month 6. RESULTS: A total of 436 patients (mean age: 54.4 years; women: 73.4%) were included, 222 in the ACS arm and 214 patients in the usual treatment arm, which was mainly antispasmodics. At 6 months, improvement of IBSQoL was greater with ACS than with the usual treatment group (13.8 vs. 8.4; p < 0.0008). The IBS-severity symptom score (IBS-SSS) was lower with ACS than in the usual treatment arm with a mean (SE) decrease of 170.0 (6.6) vs. 110.7 (6.7), respectively (p = 0.0001). An IBS-SSS < 75 was more frequent in the ACS group (37.7% vs. 16.0%; p < 0.0001). Improvement of both abdominal pain and bloating severity was also greater with the on-demand ACS treatment, which was associated with both lower direct and indirect costs. CONCLUSIONS: After 6 months, on-demand ACS treatment led to a greater improvement of QoL, reduced the burden of the disease and was more effective for IBS symptom relief than usual treatments.
Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety.[Pubmed:25199966]
Eur J Pharmacol. 2014 Nov 5;742:94-101.
Anxiety disorders are widely spread psychiatric illnesses that are a cause of major concern. Despite a consistent increase in anxiolytics, the prevalence of anxiety is static; this necessitates the development of new compounds with potential activity and minimum unwanted effects. A serotonergic (5HT) system plays an important role in pathogenesis of anxiety and predominantly involves 5HT1A receptor action in mediating anxiety-like behavior; the antagonism of 5HT1A receptor has demonstrated to produce anxiolytic-like effects. Alverine Citrate (AVC) is reported as a 5HT1A antagonist; however, its effects on anxiety-like behavior are not investigated. Thus, the present study, by utilizing a neurobehavioral approach, examined the anxiolytic-like effects of AVC in experimental mouse models of anxiety. Mice were acutely treated with AVC (5-20mg/kg, i.p.)/diazepam (DIA, 2mg/kg, i.p.) and subjected to four validated anxiety models viz. elevated plus-maze (EPM), light/dark (L/D), hole-board (HB) and marble burying (MB) tests. AVC (15-20mg/kg) and DIA significantly increased open arm activity in EPM, exploration in light chamber in L/D test, exploratory behavior in HB and reduced MB behavior in marble burying test. AVC (5mg/kg) had no effect on all behavioral tests, while AVC (10mg/kg) produced partial effects. It revealed anxiolytic-like effects of AVC. Furthermore, anxiolytic-like effects of AVC at higher doses (15-20mg/kg) were more pronounced than lower doses (10mg/kg) and were quite similar to the standard drug DIA. The present finding demonstrates, for the first time, the anxiolytic-like effects of AVC, which may be an alternative approach for management of anxiety-related disorders.
